Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis

References

• Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769–786. doi: 10.1016/S0140-6736(22)01052-2.
   PubMed Web of Science ®Google Scholar
• Buschulte K, Cottin V, Wijsenbeek M, et al. The world of rare interstitial lung diseases. Eur Resp Rev. 2023;32(167):220161. doi: 10.1183/16000617.0161-2022
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748. doi: 10.1164/rccm.201308-1483ST
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. doi: 10.1164/rccm.202202-0399ST
   PubMed Web of Science ®Google Scholar
• Munchel JK, Shea BS. Diagnosis and management of idiopathic pulmonary fibrosis. R I Med J. 2021;104(7):26–29.
   Google Scholar
• Castelli G, Cocconcelli E, Bernardinello N, et al. Idiopathic pulmonary fibrosis: 8 years on after nintedanib and pirfenidone approval—what is on the horizon? Curr Pulmonol Rep. 2023;12(3):113–124. doi: 10.1007/s13665-023-00315-y
   Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–1047. doi: 10.1164/rccm.200404-571OC
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446(1–3):167–176. doi: 10.1016/s0014-2999(02)01757-0
   PubMed Web of Science ®Google Scholar
• Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-αat the translational level. Eur J Pharmacol. 2002;446(1–3):177–185. doi: 10.1016/s0014-2999(02)01758-2
   PubMed Web of Science ®Google Scholar
• Iyer SN, Margolin SB, Hyde DM, et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998;24(1):119–133. doi: 10.3109/01902149809046058
   PubMed Web of Science ®Google Scholar
• Rivera-Ortega P, Hayton C, Blaikley J, et al. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Ther Adv Respir Dis. 2018;12:1753466618800618. doi: 10.1177/1753466618800618
   Web of Science ®Google Scholar
• Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9(1):157–179. doi: 10.1146/annurev-pathol-012513-104706
   PubMed Web of Science ®Google Scholar
• Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1):32. doi: 10.1186/s12931-018-0730-2
   PubMed Web of Science ®Google Scholar
• Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:729–737. doi: 10.1164/rccm.200804-550OC
   PubMed Web of Science ®Google Scholar
• Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165(9):1322–1328. doi: 10.1164/rccm.200112-123OC
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;4(1):52–59. doi: 10.1016/j.ajhg.2008.11.010
   Google Scholar
• Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–1512. doi: 10.1056/NEJMoa1013660.
   PubMed Web of Science ®Google Scholar
• Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–317. doi: 10.1016/S2213-2600(13)70045-6
   PubMed Web of Science ®Google Scholar
• Kaur A, Mathai SK, Schwartz DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med. 2017;4:154. doi: 10.3389/fmed.2017.00154
   PubMed Web of Science ®Google Scholar
• Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: a review. Curr Pulmonol Rep. 2018;7(4):118–125. doi: 10.1007/s13665-018-0210-7
   PubMedGoogle Scholar
• Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3(4):293–298. doi: 10.1513/pats.200512-131TK
   PubMedGoogle Scholar
• Mei Q, Liu Z, Zuo H, et al. Idiopathic pulmonary fibrosis: an update on pathogenesis. Front Pharmacol. 2022;12:797292. doi: 10.3389/fphar.2021.797292
   PubMedGoogle Scholar
• John AE, Graves RH, Pun KT, et al. Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nat Commun. 2020;11(1):4659. doi: 10.1038/s41467-020-18397-6
   PubMed Web of Science ®Google Scholar
• Xia H, Diebold D, Nho R, et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med. 2008;205(7):1659–1672. doi: 10.1084/jem.20080001
   PubMed Web of Science ®Google Scholar
• Huang Y, Xie Y, Abel PW, et al. TGF-β1- induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression. Biochem Pharmacol. 2020;180:114172. doi: 10.1016/j.bcp.2020.114172
   PubMed Web of Science ®Google Scholar
• Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1426–1433. doi: 10.1183/09031936.00149614
   PubMed Web of Science ®Google Scholar
• Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–34. doi: 10.1152/ajplung.00163.2007
   PubMed Web of Science ®Google Scholar
• Phan SH. Genesis of the myofibroblast in lung injury and fibrosis. Proc Am Thorac Soc. 2012;9(3):148–152. doi: 10.1513/pats.201201-011AW
   PubMedGoogle Scholar
• Tsukui T, Sun KH, Wetter JB, et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun. 2020;11(1):1920. doi: 10.1038/s41467-020-15647-5
   PubMed Web of Science ®Google Scholar
• Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech. 2014;7(2):193–203. doi: 10.1242/dmm.012062
   PubMed Web of Science ®Google Scholar
• Zhou Z, Qu J, He L, et al. Stiff matrix instigates type I collagen biogenesis by mammalian cleavage factor I complex-mediated alternative polyadenylation. JCI Insight. 2020;5(3):e133972. doi: 10.1172/jci.insight.133972
   PubMed Web of Science ®Google Scholar
• Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010;339(1):269–280. doi: 10.1007/s00441-009-0834-6
   PubMed Web of Science ®Google Scholar
• Lee JO, Bankston LA, Arnaout MA, et al. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 1995;3(12):1333–1340. doi: 10.1016/S0969-2126(01)00271-4
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–687. doi: 10.1016/s0092-8674(02)00971-6
   PubMed Web of Science ®Google Scholar
• Zheng Y, Leftheris K. Insights into protein-ligand interactions in integrin complexes: advances in structure determinations. J Med Chem. 2020;63(11):5675–5696. doi: 10.1021/acs.jmedchem.9b01869
   PubMed Web of Science ®Google Scholar
• Humphries MJ, Symonds EJ, Mould AP. Mapping functional residues onto integrin crystal structures. Curr Opin Struct Biol. 2003;13(2):236–243. doi: 10.1016/S0959-440X(03)00035-6
   PubMed Web of Science ®Google Scholar
• Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3(3):a004994. doi: 10.1101/cshperspect.a004994
   PubMed Web of Science ®Google Scholar
• Lowell CA, Mayadas TN. Overview: studying integrins in vivo. Methods Mol Biol. 2012;757:369–397. doi: 10.1007/978-1-61779-166-6_22
   PubMedGoogle Scholar
• Milner R, Campbell IL. The integrin family of cell adhesion molecules has multiple functions within the CNS. J Neurosci Res. 2002;69(3):286–291. doi: 10.1002/jnr.10321 PMID: 12125070.
   PubMed Web of Science ®Google Scholar
• Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol. 2009;27(1):339–362. doi: 10.1146/annurev.immunol.021908.132554
   PubMedGoogle Scholar
• Koivisto L, Bi J, Häkkinen L, et al. Integrin αvβ6: Structure, function and role in health and disease. Int J Biochem Cell Biol. 2018;99:186–196. doi: 10.1016/j.biocel.2018.04.013
   PubMed Web of Science ®Google Scholar
• Huang XZ, Wu JF, Cass D, et al. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J Cell Bio. 1996;133(4):921–928. doi: 10.1083/jcb.133.4.921
   PubMed Web of Science ®Google Scholar
• Morris DG, Huang X, Kaminski N, et al. Loss of integrin alpha(v)beta6-mediated TGF-βeta activation causes Mmp12-dependent emphysema. Nature. 2003;422(6928):169–173. doi: 10.1038/nature01413
   PubMed Web of Science ®Google Scholar
• Dong X, Hudson NE, Lu C, et al. Structural determinants of integrin beta-subunit specificity for latent TGF-βeta. Nat Struct Mol Biol. 2014;21(12):1091–1096. doi: 10.1038/nsmb.2905
   PubMed Web of Science ®Google Scholar
• Shi M, Zhu J, Wang R, et al. Latent TGF-β structure and activation. Nature. 2011;474(7351):343–349. doi: 10.1038/nature10152
   PubMed Web of Science ®Google Scholar
• Nishimura SL. Integrin-mediated transforming growth factor-activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol. 2009;175(4):1362–1370. doi: 10.2353/ajpath.2009.090393
   PubMed Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319–328. doi: 10.1016/s0092-8674(00)80545-0
   PubMed Web of Science ®Google Scholar
• Jenkins RG, Su X, Su G, et al. Ligation of protease-activated receptor 1 enhances αvβ6 integrin-dependent TGFβ- activation and promotes acute lung injury. J Clin Invest. 2006;116(6):1606–1614. doi: 10.1172/JCI27183
   PubMed Web of Science ®Google Scholar
• Goodwin A, Jenkins G. Role of integrin-mediated TGF-β activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans. 2009;37(4):849–854. doi: 10.1042/BST0370849
   PubMed Web of Science ®Google Scholar
• Zhang Z, Morla AO, Vuori K, et al. The αvβ1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J Cell Bio. 1993;122(1):235–242. doi: 10.1083/jcb.122.1.235
   PubMed Web of Science ®Google Scholar
• Reed NI, Jo H, Chen C, et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med. 2015;7(288):288ra79. doi: 10.1126/scitranslmed.aaa5094.
   PubMed Web of Science ®Google Scholar
• Sheppard D. Integrin-mediated activation of latent transforming growth factor β. Cancer Metastasis Rev. 2005;24(3):395–402. doi: 10.1007/s10555-005-5131-6
   PubMed Web of Science ®Google Scholar
• Mooney JJ, Morris K, Jacobs S, et al. PLN-74809, a dual-selective inhibitor of integrins αvβ6 and αvβ1, shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 2022;205:A5254.
   Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65. doi: 10.1164/rccm.200706-805OC
   PubMed Web of Science ®Google Scholar
• Decaris M, Schaub JR, Chen C, et al. Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021;22(1):265. doi: 10.1186/s12931-021-01863-0
   PubMed Web of Science ®Google Scholar
• Lancaster LH, Cottin V, Ramaswamy M, et al. Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF study. Am J Respir Crit Care Med. 2024. doi: 10.1164/rccm.202403-0636OC
   Google Scholar
• Wuyts WA, Valenzuela C, Jenkins G, et al. Late breaking abstract-safety, tolerability and antifibrotic activity of bexotegrast: phase 2a INTEGRIS-IPF study (NCT04396756). Eur Resp J. 2023;62:OA1423. doi: 10.1183/13993003
   Web of Science ®Google Scholar
• Slack RJ, Macdonald SJF, Roper JA, et al. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov. 2022;21(1):60–78. doi: 10.1038/s41573-021-00284-4
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65. doi: 10.1164/rccm.200706-805OC
   PubMed Web of Science ®Google Scholar
• Raghu G, Mouded M, Prasse A, et al. Randomized phase IIa clinical study of an anti-avb6 monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2022;206(9):1166–1168. doi: 10.1164/rccm.202205-0868LE
   PubMed Web of Science ®Google Scholar
• Raghu G, Mouded M, Chambers DC, et al. A phase IIb randomized clinical study of an anti-αvβ6 monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2022;206(9):1128–1139. doi: 10.1164/rccm.202112-2824OC
   PubMed Web of Science ®Google Scholar
• Wilkinson AL, John AE, Barrett JW, et al. Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease. Eur J Pharmacol. 2021;913:174618. doi: 10.1016/j.ejphar.2021.174618
   PubMed Web of Science ®Google Scholar
• Maher TM, Simpson JK, Porter JC, et al. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respir Res. 2020;21(1):75. doi: 10.1186/s12931-020-01339-7
   PubMed Web of Science ®Google Scholar
• Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin αvβ6 by [18F] FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL study). Eur J Nucl Med Mol Imaging. 2020;47(4):967–979. doi: 10.1007/s00259-019-04586-z
   PubMed Web of Science ®Google Scholar
• Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Sig Transduct Target Ther. 2023;8(1):2059–3635. doi: 10.1038/s41392-022-01259-6
   Web of Science ®Google Scholar
• Dziewierz A, Rakowski T, Dudek D. Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives. Ther Clin Risk Manag. 2014;10:567–576. doi: 10.2147/TCRM.S50002
   PubMed Web of Science ®Google Scholar
• Bansal AB, Sattar Y, Jamil RT. Eptifibatide. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2023 Apr 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541066/
   Google Scholar
• Lu WZ, Lin HA, Hou SK, et al. Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: a frequentist and Bayesian meta-analysis. Vasc Pharmacol. 2023;153:107244. doi: 10.1016/j.vph.2023.107244
   PubMed Web of Science ®Google Scholar
• Elkhawaga OY, Ellety MM, Mofty SO, et al. Review of natural compounds for potential psoriasis treatment. Inflammopharmacology. 2023;31(3):1183–1198. doi: 10.1007/s10787-023-01178-0
   PubMed Web of Science ®Google Scholar
• Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 2011;1:154–188. doi: 10.7150/thno/v01p0154
   PubMed Web of Science ®Google Scholar
• Babaesfahani A, Khanna NR, Kuns B. Natalizumab. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2022 Apr 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534201/
   Google Scholar
• Singh H, Grewal N, Arora E, et al. Vedolizumab: a novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016;7(1):4–9. doi: 10.4103/0976-9668.175016
   PubMedGoogle Scholar
• Haber SL, Benson V, Buckway CJ, et al. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:11. doi: 10.1177/2515841419870366
   Web of Science ®Google Scholar
• Karlsen TH, Folders T, Thorburn D, et al. Primary sclerosing cholangitis – a comprehensive review. J Hepatol. 2017;67(6):1298–1323. doi: 10.1016/j.jhep.2017.07.022
   PubMed Web of Science ®Google Scholar
• Rabiee A, Silveira MG. Primary sclerosing cholangitis. Transl Gastroenterol Hepatol. 2021;6:29. doi: 10.21037/tgh-20-266
   PubMed Web of Science ®Google Scholar
• Rahman SR, Roper JA, Grove JI, et al. Integrins as a drug target in liver fibrosis. Liver Int. 2022;42(3):507–521. doi: 10.1111/liv.15157
   PubMed Web of Science ®Google Scholar
• Fabregat I, Moreno-Càceres J, Sánchez A, et al. TGF-β signalling and liver disease. FEBS J. 2016;283(12):2219–2232. doi: 10.1111/febs.13665
   PubMed Web of Science ®Google Scholar
• Patsenker E, Popov Y, Stickel F, et al. Inhibition of Integrin αvβ6 on cholangiocytes blocks transforming growth factor-β activation and retards biliary fibrosis progression. Gastroenterology. 2008;135(2):660–670. doi: 10.1053/j.gastro.2008.04.009
   PubMed Web of Science ®Google Scholar
• Maher TM, Ford P, Brown KK, et al. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA. 2023;329(18):1567–1578. doi: 10.1001/jama.2023.5355
   PubMed Web of Science ®Google Scholar
• Richeldi L, Schiffman C, Behr J, et al. Zinpentraxin Alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial. Am J Respir Crit Care Med. 2024;209(9):1132–1140. doi: 10.1164/rccm.202401-0116OC
   PubMed Web of Science ®Google Scholar
• Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi: 10.1016/S2213-2600(19)30262-0
   PubMed Web of Science ®Google Scholar